 This month, two groundbreaking deals in cannabis were announced the acquisition of GW Pharmaceuticals by Jazz Pharmaceuticals and the combination of the multi-state operator MSO Parallel with the special purpose acquisition company SPAC, Ceres Acquisition Corp. The proximity of two such large deals in one month begs the question: Are the GW Pharma Jazz and Ceres Parallel deals an important barometer to the direction of cannabis, both in North America and abroad? 